BioStem Technologies (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced the appointment of Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026. Ms. Gorrell brings over two decades of experience advising healthcare organizations on regulatory, governance, and growth initiatives.
In her new role, Ms. Gorrell will oversee BioStem’s legal and compliance functions and play a central role in enterprise governance, including the integration and oversight of Medical Affairs through the company’s compliance framework. This appointment comes as BioStem implements its next phase of growth, with a focus on scaling operations and progressing toward a Nasdaq uplisting.
Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated, “Katherine is a key addition to BioStem as we implement our next phase of growth. Katherine brings a demonstrated ability to partner effectively with boards and executive teams, and her leadership will support our continued scaling while reinforcing our strong foundation of integrity and compliance, especially as we progress toward a Nasdaq uplisting.”
Ms. Gorrell most recently served as Vice President and General Counsel at Holy Cross Health in Fort Lauderdale, FL, where she was a member of the Executive Team and led legal strategy across a complex healthcare enterprise. She previously served as General Counsel and Compliance Officer for AdvancedMD, a national healthcare IT company, and held in-house roles at Intermountain Healthcare and Providence Health & Services/Swedish Health Services. Ms. Gorrell holds a JD with Honors, with a concentration in Health Law, from the University of Washington School of Law, and a Bachelor of Arts with Honors in Political Science from the University of Utah.
“BioStem is at a pivotal time in its growth and evolution. I look forward to working with the leadership team and board to support sustainable growth, strengthen governance, and ensure our legal, compliance, and medical affairs functions continue to evolve with the business,” said Katherine Gorrell.
BioStem Technologies is a publicly traded biomedical innovator focused on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its proprietary BioRetain®, CryoTek® and SteriTek® processing technologies to preserve the natural properties of these tissues for clinical use. Its quality management system is accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and current Good Manufacturing Processes. The company’s product portfolio includes Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.
The appointment of Ms. Gorrell signals BioStem’s commitment to strengthening its governance and compliance infrastructure as it scales. For investors and industry observers, this move underscores the company’s preparation for a potential Nasdaq uplisting, which could increase visibility and liquidity. The addition of a seasoned legal executive with deep healthcare regulatory experience positions BioStem to navigate complex regulatory landscapes while pursuing growth in the regenerative medicine market.
For more information on BioStem Technologies, visit the company’s website. The latest news and updates relating to $BSEM are available in the company’s newsroom at https://tinyurl.com/bsemnewsroom.
